Impact of prior vaccination on clinical outcomes of patients with COVID-19

References

• Pollard CA, Morran MP, Nestor-Kalinoski AL. The COVID-19 pandemic: a global health crisis. Physiol Genomics. 2020;52(11):549–557.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO coronavirus (COVID-19) dashboard. Available from: https://covid19.who.int/ (accessed 26 January 2022).
   Google Scholar
• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062.
   PubMed Web of Science ®Google Scholar
• Mouliou DS, Kotsiou OS, Gourgoulianis KI. Estimates of COVID-19 risk factors among social strata and predictors for a vulnerability to the infection. Int J Environ Res Public Health. 2021;18(16):8701.
   PubMed Web of Science ®Google Scholar
• Matta S, Chopra KK, Arora VK. Morbidity and mortality trends of COVID 19 in top 10 countries. Indian J Tuberc. 2020;67(4s):S167–s172.
   PubMedGoogle Scholar
• Villar J, Ariff S, Gunier RB, et al. Maternal and neonatal morbidity and mortality among pregnant women with and without COVID-19 infection: The INTERCOVID multinational cohort study. JAMA Pediatr. 2021;175(8):817–826.
   PubMed Web of Science ®Google Scholar
• World Health Organization. COVID-19 advice for the public: Getting vaccinated. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines/advice (accessed 25 January 2022).
   Google Scholar
• Falsey AR, Sobieszczyk ME, Hirsch I, et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine. N Engl J Med. 2021;385(25):2348–2360.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603–2615.
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416.
   PubMed Web of Science ®Google Scholar
• Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against COVID-19. N Engl J Med. 2021;384(23):2187–2201.
   PubMed Web of Science ®Google Scholar
• Bergwerk M, Gonen T, Lustig Y, et al. COVID-19 breakthrough infections in vaccinated health care workers. N Engl J Med. 2021;385(16):1474–1484.
   PubMed Web of Science ®Google Scholar
• Brosh-Nissimov T, Orenbuch-Harroch E, Chowers M, et al. BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel. Clin Microbiol Infect. 2021;27(11):1652–1657.
   PubMed Web of Science ®Google Scholar
• Lipsitch M, Krammer F, Regev-Yochay G, et al. SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact. Nat Rev Immunol. 2022;22(1):57–65.
   PubMed Web of Science ®Google Scholar
• Tenforde MW, Self WH, Adams K, et al. Association between mRNA vaccination and COVID-19 hospitalization and disease severity. Jama. 2021;326(20):2043–2054.
   PubMed Web of Science ®Google Scholar
• García LF. Immune response, inflammation, and the clinical spectrum of COVID-19. Front Immunol. 2020;11:1441.
   PubMed Web of Science ®Google Scholar
• Mouliou DS, Gourgoulianis KI. COVID-19 ‘asymptomatic’ patients: an old wives’ tale. Expert Rev Respir Med. 2022;16(4):399–407.
   PubMed Web of Science ®Google Scholar
• Han X, Fan Y, Alwalid O, et al. Six-month follow-up chest CT findings after severe COVID-19 pneumonia. Radiology. 2021;299(1):E177–e186.
   PubMed Web of Science ®Google Scholar
• Li X, Shen C, Wang L, et al. Pulmonary fibrosis and its related factors in discharged patients with new corona virus pneumonia: a cohort study. Respir Res. 2021;22(1):203.
   PubMed Web of Science ®Google Scholar
• Mylvaganam RJ, Bailey JI, Sznajder JI, et al. Recovering from a pandemic: pulmonary fibrosis after SARS-CoV-2 infection. Eur Respir Rev. 2021;30(162):210194.
   PubMed Web of Science ®Google Scholar
• Kim SB, Ryoo S, Huh K, et al. Revised Korean Society of Infectious diseases/national evidence-based healthcarea Collaborating Agency guidelines on the treatment of patients with COVID-19. Infect Chemother. 2021;53(1):166–219.
   PubMed Web of Science ®Google Scholar
• Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397(10287):1819–1829.
   PubMed Web of Science ®Google Scholar
• Bernal J L, Andrews N, Gower C, et al. Effectiveness of the pfizer-BioNTech and Oxford-AstraZeneca vaccines on COVID-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. Br Med J. 2021;373: n1088.
   PubMed Web of Science ®Google Scholar
• Butt AA, Omer SB, Yan P, et al. SARS-CoV-2 vaccine effectiveness in a high-risk national population in a real-world setting. Ann Intern Med. 2021;174(10):1404–1408.
   PubMed Web of Science ®Google Scholar
• Chemaitelly H, Tang P, Hasan MR, et al. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. N Engl J Med. 2021;385(24):e83.
   PubMed Web of Science ®Google Scholar
• Katikireddi SV, Cerqueira-Silva T, Vasileiou E, et al. Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil. Lancet. 2022;399(10319):25–35.
   PubMed Web of Science ®Google Scholar
• Tartof SY, Slezak JM, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021;398(10309):1407–1416.
   PubMed Web of Science ®Google Scholar
• Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513.
   PubMed Web of Science ®Google Scholar
• Carfì A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. Jama. 2020;324(6):603–605.
   PubMed Web of Science ®Google Scholar
• Zhao YM, Shang YM, Song WB, et al. Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. EClinicalMedicine. 2020;25:100463.
   PubMedGoogle Scholar
• Huang Y, Tan C, Wu J, et al. Impact of coronavirus disease 2019 on pulmonary function in early convalescence phase. Respir Res. 2020;21(1):163.
   PubMed Web of Science ®Google Scholar
• Shah AS, Wong AW, Hague CJ, et al. A prospective study of 12-week respiratory outcomes in COVID-19-related hospitalisations. Thorax. 2021;76(4):402–404.
   PubMed Web of Science ®Google Scholar
• Regev-Yochay G, Amit S, Bergwerk M, et al. Decreased infectivity following BNT162b2 vaccination: A prospective cohort study in Israel. Lancet Reg Health Eur. 2021;7:100150.
   PubMedGoogle Scholar
• Naaber P, Tserel L, Kangro K, et al. Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. Lancet Reg Health Eur. 2021;10:100208.
   PubMedGoogle Scholar
• Doria-Rose N, Suthar MS, Makowski M, et al. Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for COVID-19. N Engl J Med. 2021;384(23):2259–2261.
   PubMed Web of Science ®Google Scholar
• Berlin DA, Gulick RM, Martinez FJ. Severe COVID-19. N Engl J Med. 2020;383(25):2451–2460.
   PubMed Web of Science ®Google Scholar
• Schmidt AL, Labaki C, Hsu CY, et al. COVID-19 vaccination and breakthrough infections in patients with cancer. Ann Oncol. 2022;33(3):340–346.
   PubMed Web of Science ®Google Scholar
• Papagoras C, Fragoulis GE, Zioga N, et al. Better outcomes of COVID-19 in vaccinated compared to unvaccinated patients with systemic rheumatic diseases. Ann Rheum Dis. 2021;annrheumdis-2021-221539.
   Web of Science ®Google Scholar
• Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the lombardy region, Italy. Jama. 2020;323(16):1574–1581.
   PubMed Web of Science ®Google Scholar
• Centre for Disease Prevention and Control. Underlying medical conditions associated with high risk for severe COVID-19: information for healthcare providers. Available from: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html (accessed 11 February 2020).
   Google Scholar
• Ryu S, Kim D, Lim JS, et al. Serial interval and transmission dynamics during SARS-CoV-2 delta variant predominance, South Korea. Emerg Infect Dis. 2022;28(2):407–410.
   PubMed Web of Science ®Google Scholar
• CDC data tracker. Variant proportions. 2022. Available from: https://covid.cdc.gov/covid-data-tracker/#variant-proportions (accessed 28 Jaunary 2022).
   Google Scholar
• European Centre for Disease Prevention and Control. Weekly epidemiological update: Omicron variant of concern (VOC) – week 1 (data as of 7 January 2022) EU/EEA. 2022. Available from: https://www.ecdc.europa.eu/en/news-events/weekly-epidemiological-update-omicron-variant-concern-voc-week-1-data-7-january-2022 (accessed 29 January 2022).
   Google Scholar
• Gruell H, Vanshylla K, Tober-Lau P, et al. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. Nat Med. 2022;28(3):477–480.
   PubMed Web of Science ®Google Scholar
• Cheng SMS, Mok CKP, Leung YWY, et al. Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination. Nat Med. 2022;28(3):486–489.
   PubMed Web of Science ®Google Scholar